Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report by Schriber, Jeffrey R. et al.
Hispanics Have the Lowest Stem Cell Transplant Utilization
Rate for Autologous Hematopoietic Cell Transplantation for
Multiple Myeloma in the United States: A CIBMTR Report
Jeffrey R. Schriber, MD1,2; Parameswaran N. Hari, MD, MS3; Kwang Woo Ahn, PhD3,4; Mingwei Fei, MS3;
Luciano J. Costa, MD, PhD5; Mohamad A. Kharfan-Dabaja, MD6; Miguel Angel-Diaz, MD7; Robert P. Gale, MD8;
Siddharatha Ganguly, MD9; Saulius K. Girnius, MD10; Shahrukh Hashmi, MD11; Attaphol Pawarode, MD12;
David H. Vesole, MD, PhD13; Peter H. Wiernik, MD14; Baldeep M.Wirk, MD15; David I. Marks, MB, BS, PhD16;
Taiga Nishihori, MD6; Richard F. Olsson, MD, PhD, MMSc17,18; Saad Z. Usmani, MD19; Tomer M. Mark, MD, MSc20;
Yago L. Nieto, MD, PhD21; and Anita D’Souza, MD, MS 3
BACKGROUND: Race/ethnicity remains an important barrier in clinical care. The authors investigated differences in the receipt of
autologous hematopoietic cell transplantation (AHCT) among patients with multiple myeloma (MM) and outcomes based on race/
ethnicity in the United States. METHODS: The Center for International Blood and Marrow Transplant Research database was used to
identify 28,450 patients who underwent AHCT for MM from 2008 through 2014. By using data from the National Cancer Institute’s
Surveillance, Epidemiology, and End Results 18 registries, the incidence of MM was calculated, and a stem cell transplantation utiliza-
tion rate (STUR) was derived. Post-AHCT outcomes were analyzed among patients ages 18 to 75 years who underwent melphalan-
conditioned peripheral cell grafts (N 5 24,102). RESULTS: The STUR increased across all groups from 2008 to 2014. The increase was
substantially lower among Hispanics (range, 8.6%-16.9%) and non-Hispanic blacks (range, 12.2%-20.5%) compared with non-Hispanic
whites (range, 22.6%-37.8%). There were 18,046 non-Hispanic whites, 4123 non-Hispanic blacks, and 1933 Hispanic patients. The His-
panic group was younger (P < .001). Fewer patients older than 60 years underwent transplantation among Hispanics (39%) and non-
Hispanic blacks (42%) compared with non-Hispanic whites (56%). A Karnofsky score <90% and a hematopoietic cell transplantation
comorbidity index score >3 were more common in non-Hispanic blacks compared with Hispanic and non-Hispanic whites (P < .001).
More Hispanics (57%) versus non-Hispanic blacks (54%) and non-Hispanic whites (52%; P < .001) had stage III disease. More Hispanics
(48%) versus non-Hispanic blacks (45%) and non-Hispanic whites (44%) had a very good partial response or better before transplan-
tation (P 5 .005). Race/ethnicity did not impact post-AHCT outcomes. CONCLUSIONS: Although the STUR increased, it remained low
and was significantly lower among Hispanics followed by non-Hispanic blacks compared with non-Hispanic whites. Race/ethnicity did
not impact transplantation outcomes. Efforts to increase the rates of transplantation for eligible patients who have MM, with an
emphasis on groups that underuse transplantation, are warranted. Cancer 2017;123:3141-9. VC 2017 American Cancer Society.
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INTRODUCTION
Recent studies have confirmed the role of upfront autolo-
gous hematopoietic cell transplantation (AHCT) in
patients with newly diagnosed multiple myeloma (MM),
even in the age of novel induction therapies.1-4 Despite
these data and continued recommendations from the
National Comprehensive Cancer Center (NCCN) that
transplantation should be considered in patients who have
symptomatic disease,5 studies from the United States sug-
gest that only approximately 30% of patients with MM
undergo transplantation.6-8 Understanding barriers is
critical to developing strategies to increase the use of
AHCT as a therapeutic option.
The role of race in the receipt and efficacy of AHCT
among patients with MM has been previously studied.8-10
Despite a significantly higher incidence of MM among
blacks compared with whites, these studies have demon-
strated lower utilization rates in blacks. It is noteworthy
that studies have also demonstrated no differences in out-
comes, such as treatment-related mortality and survival
after AHCT for MM, based on race.9,10
Data are sparse on the use and efficacy of AHCT in
other ethnic groups, especially among patients who self-
identify as Hispanic, which is the fastest growing segment
of the population in the United States. We used the Cen-
ter for International Blood and Marrow Transplant
Research (CIBMTR) and Surveillance, Epidemiology and
End Results (SEER) databases to identify differences in
transplantation receipt and outcomes in self-identified
racial and ethnic groups among patients with MM who
underwent AHCT in the United States.
MATERIALS AND METHODS
Data Source
The CIBMTR registry is a prospectively maintained
transplantation database that collects transplantation data
from over 450 centers worldwide. Data are submitted to
the Statistical Center at the Medical College of Wisconsin
in Milwaukee, where computerized checks for discrepan-
cies, physicians’ review of submitted data, and on-site
audits of participating centers ensure data quality. Col-
lected data include disease type, age, sex, self-identified
race/ethnicity, date of diagnosis, graft type, conditioning
regimen, post-transplantation disease progression, sur-
vival, and cause of death and along with all transplanta-
tions reported to the CIBMTR. Data are collected before
transplantation, 100 days and 6 months after transplanta-
tion, and annually thereafter until death or last follow-up.
Between 2008 and 2014, the CIBMTR captured from
75% to 80% of all autologous transplantations performed
in the United States. For the purposes of this study, it was
assumed that there was no systematic age, sex, or race/eth-
nicity biases in reporting AHCT to the CIBMTR.
Patients
All US patients registered with the CIBMTR for a first
AHCT for MM during the period from 2008 to 2014
were collected (N 5 28,450) and used to determine the
stem cell transplantation utilization rate (STUR). Only
first transplantations were counted. Among these, patients
ages 18 to 75 years who underwent peripheral hematopoi-
etic cells with melphalan conditioning, provided
informed consent, and had a 100-day follow-up form
reported were included in the descriptive and multivariate
analyses (N5 24,102).
The incidence of MM was obtained from the
National Cancer Institute’s SEER Program. SEER data
are derived from registries covering approximately 27.8%
of the US population; we used the SEER 18 database,
which contains patients diagnosed from 2002 through
2013. By using publicly available software, which also
provides US population estimates (SEER*Stat11), we cal-
culated incidence rates per 100,000 persons for the years
2008 through 2013. SEER provides information accord-
ing to race and ethnicity, yielding the categorization of
individuals as Hispanics (irrespective of race), non-
Hispanic blacks, and non-Hispanic whites. For patients
with MM, SEER provides information on age at diagno-
sis, sex, and prior and subsequent malignancies, but not
on staging, biologic characteristics (including chromo-
some abnormalities), or the receipt of systemic therapy,
including hematopoietic cell transplantation (HCT). We
combined MM incidence derived from the SEER pro-
gram with transplantation activity reported to the
CIBMTR for the period from 2008 to 2013 to assess the
impact of disparities in AHCT.
Statistical Analysis
An estimate of the transplantation rate was calculated.
This STUR was defined as the number of new AHCTs in
a given year divided by the number of patients with newly
diagnosed MM for that year. The number of new AHCTs
each year was calculated as the number of AHCTs
reported to the CIBMTR divided by the CIBMTR cap-
ture rate. Because the estimated CIBMTR capture rate
during this time ranged from 75% to 80%, a sensitivity
analysis was performed to provide a range to the rate of
65% for the CIBMTR AHCT transplantation capture
rate in each year.
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Patient-related, disease-related, and treatment-
related factors were compared using the chi-square test for
categorical variables and the Kruskal-Wallis test for con-
tinuous variables. The outcomes analyzed included
transplantation-related mortality, relapse/progression,
progression-free survival, and overall survival (OS). Esti-
mates of outcomes were reported as probabilities with
95% confidence intervals (CIs). The probability of OS
was calculated using the Kaplan-Meier estimator, and var-
iance was estimated with the Greenwood formula. Sur-
vival curves were compared using the log-rank test.
Multivariate analysis on OS was performed using a Cox
proportional-hazards model with race/ethnicity as the
main effect. We explored interactions between the main
effect and the variables in the final model. The assump-
tion of proportional hazards was tested for each variable,
and factors that violated the proportionality assumption
were adjusted by stratification. Potential interactions
between the main effect and all other significant risk fac-
tors were tested. All P values are 2-sided; and, given the
large sample size, P values < .01 were considered signifi-
cant, a priori.
RESULTS
Table 1 shows the incidence rate of MM calculated using
the SEER database for the years 2008-2013. Next, the
STUR was calculated (Supporting Table 1; see online
supporting information). The incidence of MM in the
Hispanic and non-Hispanic white groups remained stable
during this period at an incidence rate of 5.6 to 6.3 per
100,000 for Hispanics and 5.7 to 6.0 per 100,000 for
non-Hispanic whites. In the non-Hispanic black group,
the incidence of MM was nearly double at 12.7 to 13.7
per 100,000 during this period. The overall STUR esti-
mate was 19.1% (95% CI, 18.5%-19.6%) in 2008 and
increased to 30.8% (95% CI, 30%-31.6%) in 2013.
When parsed between the 3 racial/ethnic groups, the
STUR estimate increased across all 3 groups from 8.6%
(95% CI, 7.9%-9.4%) in 2008 to 16.9% (95% CI,
15.6%-18.3%) in 2013 for Hispanics, from 12.2% (95%
CI, 11.4%-13%) in 2008 to 20.5% (95% CI, 19.4%-
21.8%) in 2013 for non-Hispanic blacks, and from
22.6% (95% CI, 21.8%-23.9%) in 2008 to 37.8% (95%
CI, 35.5%-38%) in 2013 for non-Hispanic whites.
Table 2 lists the characteristics of 24,102 patients
ages 18 to 75 years who underwent a first AHCT for MM
that was reported to the CIBMTR between 2008 and
2014, received melphalan conditioning and underwent a
peripheral HCT, and had at least 100 days of follow-up
using CIBMTR registration-level data, which captured
from 75% to 80% of MM AHCT activity in the United
States during the period. In this cohort, we identified
18,046 non-Hispanic whites, 1933 Hispanics, and 4123
non-Hispanic blacks who underwent transplantation.
There were significant differences in pretransplanta-
tion characteristics between groups. The Hispanic group
was younger, with a median age of 57 years (range, 19-75
years) versus non-Hispanic blacks (median age, 58 years;
range, 20-75 years) and non-Hispanic whites (median
age, 61 years; range, 19-75 years; P < .001). Fewer
patients aged >60 years underwent transplantation in the
Hispanic (39%) and non-Hispanic black (42%) groups
versus the non-Hispanic white group (56%; P < .001).
More women than men underwent transplantation in the
non-Hispanic black (50%) and Hispanic (43%) groups
versus the non-Hispanic white group (41%; P < .001). A
greater proportion of non-Hispanic blacks (44%) had
lower Karnofsky scores (<90%) compared with Hispanics
and non-Hispanic whites (39% each; P < .001). Simi-
larly, a higher proportion of non-Hispanic blacks (38%)
TABLE 1. Stem Cell Transplantation Utilization Rates in Patients With Multiple Myeloma
Hispanic Non-Hispanic Black Non-Hispanic White
Year
Incidence
(95% CI)
STUR Estimate
(95% CI), %
Incidence
(95% CI)
STUR Estimate
(95% CI), %
Incidence
(95% CI)
STUR Estimate
(95% CI), %
Overall STUR
Estimate
(95% CI), %
2008 5.8 (5.3-6.3) 8.6 (7.9-9.4) 12.6 (11.7-13.4) 12.2 (11.4-13) 5.7 (5.5-5.9) 22.6 (21.8-23.9) 19.1 (18.5-19.6)
2009 5.9 (5.4-6.4) 9.8 (9.0-10.7) 12.9 (12.1-13.8) 13.2 (12.4-14) 5.7 (5.5-5.9) 26.6 (25.7-27.5) 21.9 (21.3-22.5)
2010 6.0 (5.5-6.5) 11.9 (10.9-13) 12.9 (12.2-13.8) 15.7 (14.8-16.8) 6.0 (5.8-6.2) 29.4 (28.4-30.4) 24.7 (24.1-25.4)
2011 6.3 (5.9-6.9) 11.4 (10.6-12.4) 13.3 (12.5-14.1) 18.2 (17.1-19.3) 5.9 (5.7-6.1) 34 (32.9-35.1) 27.8 (27.1-28.6)
2012 6.2 (5.7-6.7) 14.2 (13.1-15.4) 13.7 (12.9-14.5) 19 (18-20.2) 6.0 (5.8-6.2) 35.4 (34.3-36.6) 29.5 (28.8-30.3)
2013 5.6 (5.2-6.1) 16.9 (15.6-18.3) 13.3 (12.5-14.1) 20.5 (19.4-21.8) 5.8 (5.6-6.0) 37.8 (35.5-38) 30.8 (30-31.6)
Abbreviations: CI, confidence interval STUR, stem cell transplantation utilization rate.
a The incidence rate is age-adjusted and shown per 100,000 population, and the STUR is expressed as a percentage; both rates include 95% CIs in
parentheses.
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and non-Hispanic whites (34%) had higher HCT-
comorbidity index (HCT-CI) scores 3 compared with
Hispanics (24%; P < .001). Advanced disease stage
(Durie-Salmon or International Staging System stage III)
was more common among the Hispanic (57%) and non-
Hispanic black (54%) groups versus the non-Hispanic
white group (52%; P < .001). A greater proportion of
non-Hispanic whites proceeded to transplantation <6
months after diagnosis (30%) compared with Hispanics
(23%) and non-Hispanic blacks (21%; P < .001). More
Hispanics (48%) patients were in a very good partial
response (VGPR) or better disease status at the time of
AHCT compared with non-Hispanic black patients
(45%) and non-Hispanic white patients (44%; P< .005).
Next, we characterized further details of the 1933
Hispanic patients who proceeded to transplantation (Table
3). The majority (N5 1590) identified as Hispanic white,
64 identified as Hispanic black, and 279 as identified as
Hispanic other. There were no differences between these
groups noted for age, sex, Karnofsky score, HCT-CI score,
time to transplantation, or pretransplantation staging.
There were more patients with stage III disease in the His-
panic white group (59%) compared with the Hispanic
black (55%) andHispanic other groups (47%; P5 .008).
TABLE 2. Patient Characteristics (N 5 24,102)
No. of Patients (%)
Variable Hispanic Non-Hispanic Black Non-Hispanic White P
No. of enrolled patients 1933 4123 18046
No. of centers 111 126 135
Patient-related variables
Age at transplantation: Median [range], y 57 [19-75] 58 [20-75] 61 [19-75] < .001
<45 213 (11) 395 (10) 838 (5)
45-60 972 (50) 2003 (49) 7164 (40)
61-75 748 (39) 1725 (42) 10044 (56)
Sex, men 1097 (57) 2062 (50) 10693 (59) < .001
Karnofsky score <90% 750 (39) 1807 (44) 7116 (39) < .001
HCT-CI index < .001
No comorbidity 618 (32) 920 (22) 5043 (28)
1-2 639 (33) 1241 (30) 5353 (30)
3 465 (24) 1587 (38) 6209 (34)
Missing 211 (11) 375 (9) 1441 (8)
Disease-related variables
Immunochemical subtype < .001
IgG 1055 (55) 2652 (64) 10154 (56)
IgA 410 (21) 662 (16) 3899 (22)
Light chain 399 (21) 725 (18) 3469 (19)
Nonsecretory 41 (2) 61 (1) 302 (2)
Others 28 (1) 22 (<1) 221 (1)
Missing 0 1 (<1) 1 (<1)
Advanced stage at diagnosis: ISS/DSS III 1100 (57) 2216 (54) 9379 (52) < .001
Time from diagnosis to transplantation, mo < .001
<6 436 (23) 860 (21) 5454 (30)
6-12 860 (44) 1839 (45) 7864 (44)
>12 634 (33) 1420 (34) 4699 (26)
Missing 3 (<1) 4 (<1) 29 (<1)
Transplantation-related variables
Melphalan dose 200 mg/m2 1636 (85) 3488 (85) 15469 (86) .29
Disease status before transplantation .005
sCR/CR 315 (16) 571 (14) 2551 (14)
VGPR 611 (32) 1260 (31) 5388 (30)
PR 787 (41) 1809 (44) 8079 (45)
SD/relapse/progression 212 (11) 476 (12) 1953 (11)
Missing 8 (<1) 7 (<1) 75 (<1)
Planned post-transplantation therapy < .001
No 1571 (81) 3205 (78) 13426 (74)
Yes 360 (19) 914 (22) 4585 (25)
Missing 2 (<1) 4 (<1) 35 (<1)
Follow-up of survivors: Median [range], mo 36 (1-99) 37 (1-97) 38 (1-98)
Abbreviations: CR, complete response; DSS, Durie-Salmon staging; HCT-CI, hematopoietic cell transplantation-comorbidity index; IgA, immunoglobulin A; IgG,
immunoglobulin G; ISS, International Staging System; PR, partial response; SD, stable disease; sCR, stringent complete response; VGPR, very good partial
response.
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Post-transplantation outcomes are detailed in
Table 4. No difference was observed between the differ-
ent racial and ethnic groups for transplantation-related
mortality, progression-free survival, or OS (Fig. 1). On
multivariate analysis (Table 5), race and ethnicity had
no influence on survival (Table 5); however older age
(range, 61-75 years), male sex, a Karnofsky score
<90%, an HCT-CI score 3, a longer interval from
diagnosis to transplantation (>12 months), a lower mel-
phalan dose for conditioning (140 mg/m2), and adverse
disease status (complete response or worse) before trans-
plantation adversely affected survival.
DISCUSSION
MM is 1 of the model cancers in which survival for
patients has increased considerably during the first decade
of the 21st century. However, this improvement has not
increased across all racial/ethnic strata in the United
States. Multiple studies have demonstrated disparities in
outcomes among patients with MM using SEER data.
Pulte et al reported an improvement in age-adjusted, 5-
year relative survival for patients with MM, with an
increase from 35.6% during 1998 through 2001 to 44%
during 2006 through 2009.12 However, this increase was
greatest for non-Hispanic whites, and excess mortality
TABLE 3. Characteristics of Hispanic patients (N 5 1933)
No. of Patients (%)
Variable Hispanic White Hispanic Black Hispanic Others P
No. of enrolled patients 1590 64 279
No. of centers 102 32 54
Patient-related variables
Age at transplantation: Median [range], y 57 [19-75] 57 [40-74] 57 [28-74] .46
<45 184 (12) 4 (6) 25 (9)
45-60 793 (50) 32 (50) 147 (53)
61-75 613 (39) 28 (44) 107 (38)
Sex, men 907 (57) 30 (47) 160 (57) .27
Karnofsky score <90% 621 (39) 28 (44) 101 (36) .72
HCT-CI index .09
No comorbidity 502 (32) 19 (30) 97 (35)
1-2 524 (33) 15 (23) 100 (36)
3 381 (24) 23 (36) 61 (22)
Missing 183 (12) 7 (11) 21 (8)
Clinical trial enrollment 51 (3) 1 (2) 13 (5) .33
Disease-related variables
Immunochemical subtype .67
IgG 862 (54) 36 (56) 157 (56)
IgA 340 (21) 11 (17) 59 (21)
Light chain 332 (21) 15 (23) 52 (19)
Nonsecretory 35 (2) 2 (3) 4 (1)
Others 21 (1) 0 7 (3)
ISS/DSS III 934 (59) 35 (55) 131 (47) .008
Time from diagnosis to transplantation, mo .52
<6 369 (23) 12 (19) 55 (20)
6-12 711 (45) 26 (41) 123 (44)
>12 508 (32) 26 (41) 100 (36)
Missing 2 0 1
Transplantation-related variables
Melphalan dose 200 mg/m2 1336 (84) 51 (80) 249 (89) .04
Disease status before transplantation .98
sCR/CR 259 (16) 10 (16) 46 (16)
VGPR 499 (31) 18 (28) 94 (34)
PR 653 (41) 27 (42) 107 (38)
SD/relapse/progression 172 (11) 9 (14) 31 (11)
Missing 7 (<1) 0 1 (<1)
Planned post-transplantation therapy .03
No 1294 (81) 60 (94) 217 (78)
Yes 295 (19) 4 (6) 61 (22)
Missing 1 (<1) 0 1 (<1)
Follow-up of survivors: Median [range], mo 37 [1-99] 37 [4-74] 25 [1-82]
Abbreviations: CR, complete response; DSS, Durie-Salmon staging; HCT-CI, hematopoietic cell transplantation-comorbidity index; IgA, immunoglobulin A; IgG,
immunoglobulin G; ISS, International Staging System; PR, partial response; SD, stable disease; sCR, stringent complete response; VGPR, very good partial
response.
Race/Ethnicity and Transplant in Myeloma/Schriber et al
Cancer August 15, 2017 3145
hazard ratios were observed among non-Hispanic blacks
and Hispanics compared with non-Hispanic whites,12
suggesting that ethnic minorities may have not benefited
from the advances in MM therapies to a similar extent as
non-Hispanic whites. Ailawadhi et al also reported similar
findings using SEER 17 registry data.13
Although AHCT is not a new therapy in MM,
despite the availability of several novel therapies, it
remains an important treatment option, especially in the
upfront setting, based on numerous recent studies.1-3,14
We conducted the current research to better understand
disparities in transplantation use in the United States. In
this large database study, which captures the majority of
MM AHCT activity in the United States, we make the
following observations: 1) The STUR in MM has
improved significantly from 2008 to 2013; 2) however,
despite the increase, the overall STUR was only 30.8% in
2013 and was lowest among Hispanics followed by non-
Hispanic blacks and was highest among non-Hispanic
whites; 3) Hispanic patients who undergo AHCT for
MM tend to be younger, fitter, and have more advanced
disease; and 4) race/ethnicity did not impact post-AHCT
MMoutcomes.
Despite compelling evidence and NCCN recom-
mendations5 that patients with MM should be evaluated
at a stem cell transplantation center, the rate of transplan-
tation use remained low, at approximately 30.8% in
2013. Despite an almost doubling of the STUR from
8.6% to 16.9% among Hispanics and a 70% increase in
the STUR among blacks from 12.2% to 20.5%, the rate
remained substantially lower than that among non-
Hispanic whites, for whom it rose from 22.6% to 37.8%
in the same time frame. In addition, the increased rate of
patients who underwent transplantation from 2008 to
TABLE 4. Univariate Outcomes of Patients Characterized by Race and Ethnicity (N 5 24,102)
Hispanic, N 5 1933 Non-Hispanic Black, N 5 4123 Non-Hispanic White, N 5 18,046
Outcome No. of Patients Prob (95% CI), % No. of Patients Prob (95% CI), % No. of Patients Prob (95% CI), % P
NRM 1926 4104 18,006 .36a
100-Day 0.6 (0.3-1) 0.6 (0.4-0.9) 0.9 (0.7-1) .15
1-Year 2 (2-3) 3 (2-3) 3 (2-3) .70
PFS 1926 4104 18,006 1.0a
1-Year 82 (80-84) 82 (81-83) 83 (82-83) .30
2-Year 66 (64-68) 66 (64-67) 66 (65-67) .93
3-Year 54 (51-56) 54 (52-55) 53 (52-54) .84
OS 1932 4120 18,030 .13a
1-Year 94 (93-95) 94 (94-95) 94 (93-94) .26
2-Year 86 (85-88) 86 (85-87) 86 (85-86) .72
3-Year 80 (77-82) 79 (77-80) 77 (77-78) .05
Abbreviations: CI, confidence interval; NRM, nonrelapse mortality; OS, overall survival; PFS, progression-free survival; Prob, probability.
a log rank p-value.
TABLE 5. Multivariate Analysis of Overall Survival
Effect HR (95% CI) P
Main effect .08
Hispanic 1.00
Non-Hispanic black 0.99 (0.89-1.11) .2
Non-Hispanic white 1.07 (0.97-1.18) .9
Age, y < .0001
<45 1.00
45-60 1.15 (1.02-1.30) .02
61-75 1.33(1.18-1.50) < .0001
Sex < .0001
Men 1.00
Women 0.87 (0.823-0.92)
Karnofsky score < .0001
90% 1.00
<90% 1.23 (1.19-1.32)
Missing 1.14 (1.01-1.29)
HCT-CI <.0001
No comorbidity 1.00
1-2 1.04 (0.97-1.11) .26
3 1.21 (1.13-1.29) < .0001
Missing 0.87 (0.79-0.96) .006
Stage at diagnosis < .0001
<III 1.00
III 1.46 (1.39-1.54) < .0001
Missing 1.17 (1.02-1.34) .02
Time from diagnosis to
transplantation, mo
< .0001
<6 1.00
6-12 1.08 (1.01-1.15) .03
>12 1.44 (1.34-1.54) < .0001
Missing 2.13 (1.28-3.55) .004
Melphalan dose, mg/m2 < .0001
140 1.00
200 0.85 (0.80-0.91) < .0001
Missing 0.41 (0.06-2.93) .4
Disease status at transplantation < .0001
sCR/CR 1.00
VGPR 1.22 (1.11-1.33) < .0001
PR 1.32 (1.22-1.44) < .0001
SD/relapse/progression 2.04 (1.84-2.25) < .0001
Missing 1.39 (0.85-2.28) .2
Abbreviations: CI, confidence interval; CR, complete response; HCT-CI,
hematopoietic cell transplantation-comorbidity index; HR, hazard ratio; PR,
partial response; SD, stable disease; sCR, stringent complete response;
VGPR, very good partial response.
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2013 was far greater in non-Hispanic whites (15.2%), ver-
sus non-Hispanic blacks (8.3%) and Hispanics (8.3%).
This means that Hispanic patients undergo transplanta-
tion at less than one-half the rate of non-Hispanic white
patients (45%), and non-Hispanic black patients undergo
transplantation at a just over one-half the rate (54%) of
non-Hispanic white patients. Others have also reported
that non-Hispanic black and Hispanic patients with MM
have a lower rate of AHCT.6,8 Al-Hamadani et al demon-
strated that older age, lower levels of education and house-
hold income, nonmanaged health care, residence in a
metropolitan area, treatment at a community center, a
treatment facility outside the Midwest and Western
regions, as well as racial and ethnic minorities are all less
likely to predict receipt of AHCT for patients with MM.6
Joshua et al previously demonstrated that transplantation,
both autologous and allogeneic, is more frequently
received by white patients than by black patients for the
treatment of treat leukemia, lymphoma andMM.10
Our data also indicate that there are differences
according to race/ethnicity in the profiles of patients who
receive AHCT for MM. Hispanic and non-Hispanic
black patients tend to be younger, and few patients aged
>60 years undergo transplantation in these groups com-
pared with the non-Hispanic white group. This is particu-
larly poignant in patients with MM, because the median
age at diagnosis of MM is 69 years.15 This finding may
also account in part for some differences in the STUR
across race/ethnicities. Hispanic and non-Hispanic black
patients were also more likely to have advanced-stage dis-
ease at diagnosis and to undergo transplantation later
from diagnosis than non-Hispanic white patients. This
confirms the results of a small, single-center study from
Baltimore indicating that, among patients with MM who
were referred for AHCT, black patients were younger and
often had delayed referrals for AHCT compared with
white patients.16 We now extend this finding to Hispanic
patients as well.
A significantly higher percentage of Hispanic
patients had lower comorbidity scores and were more
likely to have a better disease status (VGPR or better)
before transplantation compared with non-Hispanic
black and non-Hispanic white patients. This suggests that
Hispanic patients who undergo transplantation tend to be
younger, fitter, have more advanced but responsive dis-
ease, and undergo transplantation later in their disease
course than non-Hispanic white patients. Non-Hispanic
black recipients of AHCT also have a similar profile; they
too are younger, have more advanced disease, and
undergo transplantation later than non-Hispanic white
patients. In addition, they are more likely to have higher
comorbidities than non-Hispanic white and Hispanic
patients. Fiala et al demonstrated that the racial disparities
between black and white patients with MM who undergo
AHCT are not fully accounted for by age, sex, socioeco-
nomic status, insurance, and comorbidities.17 The Insti-
tute of Medicine has also reported that racial and ethnic
disparities in health care are not entirely explained by dif-
ferences in access to care, clinical appropriateness, or
patient preferences.18 Studies have also documented dif-
ferential receipt of technical aspects of care, such as tests,
therapies, and procedures, among racial/ethnic minorities
compared with whites, even after controlling for insurance
status and access to medical care.19 These data point
toward an interplay of many other complex factors, such
as physician bias, referral bias, cultural beliefs, language
barriers, and access to a transplantation center, which may
affect the receipt of AHCT among different race/ethnic
groups. One single-center study demonstrated that, once
patients attend a transplantation center, transplantation
rates are similar among different ethnic groups.20 In
another setting, namely, the treatment of patients with
MM in clinical trials in the United States, a similar differ-
ence has been reported.21
Previous literature, including reports from the
CIBMTR, has indicated that post-transplantation out-
comes are identical regardless of race.9,16,22 Our current
results extend that literature among ethnic subgroups
with identical results. With this in mind, and recognizing
the differences in the STUR, we believe it is time for a
concerted effort to improve the STUR among all groups,
with special emphasis on the low-performing ethnicities.
NCCN and other national guidelines could address the
finding that outcomes for similarly treated patients are
Figure 1. Progression-free survival (PFS) and overall survival
(OS) are illustrated by race/ethnicity.
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comparable across racial and ethnic groups, but the
STUR varies.
Our data have some limitations. Our assumption
was that there was no age, sex, or racial/ethnic bias in
reporting AHCT to the CIBMTR. It is possible but
highly unlikely that such a bias exists in the reporting of
data to the CIBMTR and that this could have influenced
the STUR across ethnic groups. We note that centers are
required to register consecutive patients, and this is aud-
ited and monitored by a robust, continuous,
performance-improvement process. Second, it is unlikely,
given the magnitude of the disparities observed, that sys-
tematic underreporting would account for the difference
in the STUR, although it could influence the patient dif-
ferences noted between ethnic groups in terms of those
who proceed to transplantation. In addition, our data are
based on only those patients who actually proceeded to
transplantation, and we cannot comment in this analysis
on those patients with MM who did not proceed to
AHCT. It is possible, that in areas with a high proportion
of Hispanic patients, transplantation centers may not be
located at an accessible distance. For instance, for the
majority of the time from 2008 through 2013, there was
not a local transplantation center for patients in New
Mexico or Nevada, where sizable shares of the state popu-
lations are Hispanic (48% and 28%, respectively).23 Eligi-
ble patients would have had to travel out of state to
undergo transplantation. Previous studies have indicated
that such barriers may decrease the receipt transplanta-
tion; and this, by itself, may be an important factor in the
lower STURs noted among Hispanics.10 Our strength,
however, is in our ability to capture of the majority of
patients with MM who underwent an AHCT in the
United States.
With clear data demonstrating no differences in out-
comes and a clear difference in transplantation utilization
by ethnic groups, it is crucial that we now perform addi-
tional studies to understand why a disproportionate num-
ber of black and Hispanic patients fail to undergo
transplantation for MM. It is also important that race and
ethnicity should be clearly delineated as factors that do
not impact outcomes in terms of proceeding to transplan-
tation. Further education on early referral to transplanta-
tion centers for all populations is critical, and efforts
should be made to expand community outreach across
racial and ethnic groups. Development of strategies to
increase access to transplantation across all ethnic groups,
with an emphasis on those who are currently underutiliz-
ing this modality, is urgently needed.
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